| |
spa resorts for sale overseas
News and Information Article
GAINESVILLE, Fla., March 9 // -- AxoGen, Inc., an early stage
medical device company, today has announced their Series B financing of $7.75
million to finance the development of a human allograph for peripheral nerve
repair and regeneration.
The Series B round was raised through a consortium of investors led by
Cardinal Partners, Accuitive Medical Ventures and De Novo Ventures. Lisa
Skeete Tatum, General Partner at Cardinal, Gerard Van Hamel Platerink,
Managing Director at Accuitive, and Joe Mandato, Managing Director at De Novo
Ventures will join the board.
AxoGen, founded in 2002, is commercializing technology developed at the
McKnight Brain Institute of the University of Florida. AxoGen provides
surgeons a biological solution to repair and regenerate peripheral nerves,
bringing relief and restoring functionality to patients who suffer peripheral
nerve injuries. The company brings to this market a unique combination of
patented technologies, an experienced management team, and a rich pipeline of
new products and technologies to address other nerve injuries. "We are
extremely excited about our opportunity to bring this biological solution to
patients to restore both sensory and motor function caused by peripheral nerve
injuries," says AxoGen Chief Executive Officer Jamie Grooms.
AxoGen is based in Gainesville, Florida.
http://www.AxoGeninc.com
http://www.cardinalpartners.com
http://www.amvpartners.com/
http://www.denovovc.com/
| |
|
|
 |
spa resorts for sale overseas |
|
|
|
|
|
|
|
|
|
Locations
